Skip to content

Inflammation Markers in Fluid Aspirate From a Scarred Uterine vs. a Normal Uterine Cavity

Inflammation Markers in Fluid Aspirate From a Scarred Uterine vs. a Normal Uterine Cavity

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06322498
Enrollment
100
Registered
2024-03-21
Start date
2023-01-18
Completion date
2024-12-31
Last updated
2024-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean Section Complications, Infertility Due to Nonimplantation, Infertility Secondary

Brief summary

A prospective study that will take place in the hydrosonography clinic, comparing patients with an intact uterus to those who had a caesarean section. Eligible patients will preform a transvaginal ultrasound for evaluation of presence of a niche. After fixation of the transcervical catheter, we will flush 2 ml sterile NaCl 0.9% into the uterine cavity and aspirate the fluid. After collecting all samples, the samples will be snap frozen and stored at -80o C, until they undergo an immunological analysis.

Interventions

DIAGNOSTIC_TESTUterine lavage

Infusion of 2ml 0.9%NACL into the uterine cavity and aspiration of the fluid

Sponsors

Hadassah Medical Organization
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

\- Patients suffering from infertility and assigned for a hydrosonography exam for assessment of the integrity of the uterus and fallopian tubes.

Exclusion criteria

1. Patients with hydrosalpinx/pyosalpinx/sactosalpinx 2. Patients who went through surgical correction of a niche 3. Hormonal treatment- estrogens or progestins. 4. Immunosuppressive/immunomodulating medication

Design outcomes

Primary

MeasureTime frameDescription
Inflammatory cell populationThrough study completion, an average of 1 yearThe wash samples are processed, supernatant discarded and RBCs removed. Cells are then washed with FACS buffer ,subjected to antibody staining and examined by flow cytometry. Antibodies include: CD45,UV,CD3,CD19,CD66B,CD88, CD89, CD14,CD16,CD314,HLA-DR in order to identify monocytes, dendritic cells, T cells, B cells, NK and Neutrophil populations

Countries

Israel

Contacts

Primary ContactChana Adler, MD
chanaa@hadassah.org.il972-50-8779068

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026